CN101516372A - 作为血清素受体调节剂的三环的茚并吡咯衍生物 - Google Patents

作为血清素受体调节剂的三环的茚并吡咯衍生物 Download PDF

Info

Publication number
CN101516372A
CN101516372A CNA2005800255071A CN200580025507A CN101516372A CN 101516372 A CN101516372 A CN 101516372A CN A2005800255071 A CNA2005800255071 A CN A2005800255071A CN 200580025507 A CN200580025507 A CN 200580025507A CN 101516372 A CN101516372 A CN 101516372A
Authority
CN
China
Prior art keywords
methyl
hexahydroindeno
pyrrole
mmol
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800255071A
Other languages
English (en)
Chinese (zh)
Inventor
Y·L·本纳尼
B·哈克
M·J·罗巴奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Athersys Inc
Original Assignee
Athersys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athersys Inc filed Critical Athersys Inc
Publication of CN101516372A publication Critical patent/CN101516372A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
CNA2005800255071A 2004-07-29 2005-07-26 作为血清素受体调节剂的三环的茚并吡咯衍生物 Pending CN101516372A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59204704P 2004-07-29 2004-07-29
US60/592,047 2004-07-29

Publications (1)

Publication Number Publication Date
CN101516372A true CN101516372A (zh) 2009-08-26

Family

ID=37075566

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800255071A Pending CN101516372A (zh) 2004-07-29 2005-07-26 作为血清素受体调节剂的三环的茚并吡咯衍生物

Country Status (16)

Country Link
US (5) US20060025601A1 (https=)
EP (1) EP1841738A4 (https=)
JP (1) JP4990164B2 (https=)
KR (2) KR101257233B1 (https=)
CN (1) CN101516372A (https=)
AR (1) AR050274A1 (https=)
AU (1) AU2005333518B2 (https=)
BR (1) BRPI0512869A (https=)
CA (1) CA2603249C (https=)
IL (1) IL180977A (https=)
NO (1) NO20071102L (https=)
NZ (1) NZ552806A (https=)
RU (1) RU2007107494A (https=)
TW (1) TWI377195B (https=)
WO (1) WO2007081299A2 (https=)
ZA (1) ZA200700684B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106631989A (zh) * 2016-11-26 2017-05-10 威海迪素制药有限公司 一种盐酸多奈哌齐有关物质e的制备方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1841738A4 (en) * 2004-07-29 2010-06-02 Athersys Inc TRICYCLIC INDENOPYRROLE DERIVATIVES AS MODULATORS OF SEROTONIN RECEPTORS
EP2742936A1 (en) 2006-05-16 2014-06-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
KR101126383B1 (ko) 2007-02-07 2012-04-12 교와 핫꼬 기린 가부시키가이샤 3환계 화합물
EP2789338A3 (en) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Condensed pyridine derivate and use thereof
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2327690A4 (en) 2008-08-06 2012-03-28 Kyowa Hakko Kirin Co Ltd TRICYCLIC CONNECTION
TW201041851A (en) 2009-03-10 2010-12-01 Organon Nv Tricyclic heterocyclic derivatives
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CN106380440B (zh) * 2016-08-30 2019-02-01 华东师范大学 一种茚酮并吡咯类衍生物及其合成方法和应用
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4622405A (en) * 1984-07-25 1986-11-11 Abbott Laboratories 1,2,3,3a,8,8a-hexahydro-indeno[1,2-c]pyrroles useful in the treatment of hypertension
DE3576334D1 (de) * 1984-07-25 1990-04-12 Abbott Lab 1,2,3,3a,8,8a-hexahydro-indeno-(1,2-c)pyrrde.
JPH03502701A (ja) * 1988-12-15 1991-06-20 アボツト・ラボラトリーズ ５‐ｈｔ選択性物質
US5049564A (en) * 1989-11-17 1991-09-17 Abbott Laboratories 5-HT selective agents
US5244888A (en) * 1989-11-17 1993-09-14 Abbott Laboratories 5-HT selective agents
TW334423B (en) * 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
US7351711B2 (en) * 2003-07-31 2008-04-01 Janssen Pharmaceutical, N.V. Tricyclic indanyls as integrin inhibitors
TWI350168B (en) * 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
EP1841738A4 (en) * 2004-07-29 2010-06-02 Athersys Inc TRICYCLIC INDENOPYRROLE DERIVATIVES AS MODULATORS OF SEROTONIN RECEPTORS

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106631989A (zh) * 2016-11-26 2017-05-10 威海迪素制药有限公司 一种盐酸多奈哌齐有关物质e的制备方法
CN106631989B (zh) * 2016-11-26 2019-07-16 威海迪素制药有限公司 一种盐酸多奈哌齐有关物质e的制备方法

Also Published As

Publication number Publication date
KR101257233B1 (ko) 2013-04-29
JP2008508365A (ja) 2008-03-21
TWI377195B (en) 2012-11-21
US20110172283A1 (en) 2011-07-14
JP4990164B2 (ja) 2012-08-01
IL180977A0 (en) 2009-02-11
AU2005333518B2 (en) 2010-12-02
WO2007081299A3 (en) 2007-09-20
RU2007107494A (ru) 2008-09-10
WO2007081299A2 (en) 2007-07-19
US20120252859A1 (en) 2012-10-04
ZA200700684B (en) 2008-10-29
US20060025601A1 (en) 2006-02-02
AU2005333518A1 (en) 2007-02-22
AR050274A1 (es) 2006-10-11
BRPI0512869A (pt) 2008-04-08
US9096520B2 (en) 2015-08-04
KR20080025657A (ko) 2008-03-21
NZ552806A (en) 2009-09-25
CA2603249C (en) 2014-01-21
TW200619196A (en) 2006-06-16
US8716324B2 (en) 2014-05-06
CA2603249A1 (en) 2007-07-19
US7935830B2 (en) 2011-05-03
EP1841738A2 (en) 2007-10-10
IL180977A (en) 2012-08-30
US20090239925A1 (en) 2009-09-24
US8232311B2 (en) 2012-07-31
KR20130047765A (ko) 2013-05-08
US20140206739A1 (en) 2014-07-24
AU2005333518A8 (en) 2008-08-07
NO20071102L (no) 2007-04-20
EP1841738A4 (en) 2010-06-02

Similar Documents

Publication Publication Date Title
US7935830B2 (en) Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators
KR101612971B1 (ko) 아미드 화합물
JP3330958B2 (ja) インドリン−２−オン誘導体、その製造方法、およびこれを含有する薬学的組成物
JP5188986B2 (ja) セロトニン５−ｈｔ２ｃ受容体のリガンドとしてのチオフェニルおよびピロリルアゼピンならびにこの使用
US20100190772A1 (en) Substituted Azepine Derivatives As Serotonin Receptor Modulators
JP3541952B2 (ja) ４−アリールイソインドール鎮痛薬
WO2025162115A1 (zh) 一种杂环化合物及其制药用途
MX2007001061A (en) Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20090826